Also listed on Tocagen, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Sep 26, 2029 · High confidence
20-year base term ends Sep 26, 2029
Held by Denovo Biopharma LLC
Filed Aug 8, 2017 as application 15/672,029 · Granted Sep 10, 2019
Base term, 20 years from filing
Today
2009
2029
Clock starts
Sep 26, 2009
Sep 26, 2009
Term ends
Sep 26, 2029
Sep 26, 2029
Granted
Sep 10, 2019
Sep 10, 2019
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 11,065,311, US 8,722,867, US 8,829,173, US 9,669,049, US 9,732,326, to Sep 26, 2029. The term already ends on or before that date, so the cap shortened nothing.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 26, 2009, when application PCT/US2009/058512, the earliest non-provisional in its chain, was filed (this one was filed Aug 8, 2017) | Sep 26, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 11,065,311, US 8,722,867, US 8,829,173, US 9,669,049, US 9,732,326) | resolves to Sep 26, 2029, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Sep 26, 2029 | High confidence |
This family
| Application PCT/US2009/058512 | PCT application no patent term | no patent term |
| US 8,829,173 | Lapsed on the fee record Sep 2018 | Sep 2018 |
| US 9,732,326 | Lapsed on the fee record Aug 2025 | Aug 2025 |
| US 10,407,666 | this patent Sep 2029 | Sep 2029 |
| Application 16/560,525 | Abandoned not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 8, 2017 Reel 44070, frame 295 | Gruber, Harry E.; Jolly, Douglas J.; Perez, Omar D.; Logg, Christopher R. | Tocagen Inc. | Assignment of Assignor's Interest |
| Nov 4, 2019 Reel 50909, frame 548 | Tocagen Inc. | Oxford Finance LLC, as Collateral Agent | Security Interest |
| Apr 23, 2020 Reel 52482, frame 439 | Oxford Finance LLC | Tocagen, Inc. | Release of Security Interest |
| Jul 13, 2020 Reel 53192, frame 140 | Tocagen Inc. | Denovo Biopharma LLC | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Sep 2029
Term ends Sep 26, 2029. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 11,065,311, US 8,722,867, US 8,829,173, US 9,669,049, US 9,732,326, ends no earlier than this term, so it caps nothing.
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2019 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.